Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Lly save search
CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight
Published: 2024-01-23 (Crawled : 22:00) - prnewswire.com
ACLX | $54.5 1.77% 1.74% 600K
|
|
| O: 1.59%
H: 1.14%
C: -1.42%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.61%
H: 1.52%
C: 0.03%
PSTX | News | $2.005 -1.72% -1.75% 520K
|
Health Technology
|
| O: 1.57%
H: 4.94%
C: 1.54%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.29%
H: 0.15%
C: -1.95%
BEAM | $24.33 0.08% 0.08% 1.7M
|
Health Technology
|
| O: 1.88%
H: 0.88%
C: -2.79%
t-cell therapy growth study market
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: -2.01%
H: 4.52%
C: -2.35%
t-cell congress therapeutics therapy
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Published: 2023-07-11 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.7%
H: 0.12%
C: -2.36%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
antibody t-cell cancer treat therapeutics
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
Published: 2023-04-27 (Crawled : 13:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: 0.26%
H: 1.82%
C: -2.21%
nktr-358 t-cell therapeutics therapy
CAR-T Cell Therapy Market Size to Reach USD 9.62 Million in 2030| Emergen Research
Published: 2023-01-09 (Crawled : 16:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.12%
H: 0.0%
C: -2.55%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.58%
H: 0.44%
C: -0.31%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.76%
H: 0.26%
C: -3.27%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.29%
H: 0.27%
C: -3.89%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.16%
H: 0.05%
C: -2.89%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 1.42%
H: 0.64%
C: -2.27%
research car-t therapy market
Novel T-Cell Immunotherapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic
Published: 2022-06-23 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.56%
H: 0.73%
C: 0.44%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 4.14%
H: 0.0%
C: 0.0%
report t-cell trial market
IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
Published: 2022-06-13 (Crawled : 02:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.12%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
car-t therapy
Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
Published: 2022-06-13 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.12%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
car-t therapy
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Published: 2022-05-11 (Crawled : 12:20) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
biopharma disease
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
Published: 2022-02-21 (Crawled : 01:00) - prnewswire.com
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
| Email alert
Add to watchlist
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
ibi345 car-t cel t-cell
Regulatory T-cells (Tregs) Therapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot
Published: 2022-02-16 (Crawled : 08:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.52%
H: 1.83%
C: 1.24%
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.36%
trial cel t-cell therapy
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
Global Immunotherapy Drugs Markets 2021-2026 - Launch of NG Immunotherapies / COVID-19 as Growth Catalyst / Approval of Novel Immunotherapy Drugs / Surge in Adoption of Car T-Cell Therapies
Published: 2021-10-28 (Crawled : 18:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.0%
H: 2.63%
C: 1.28%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.83%
H: 1.2%
C: 0.32%
covid immunotherapy therapy drug growth approval t-cell car-t
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Published: 2021-01-19 (Crawled : 12:07) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 2.74%
H: 1.8%
C: 1.27%
MRUS | $40.41 -1.56% -1.58% 240K
|
Health Technology
|
| O: 0.82%
H: 8.47%
C: 5.15%
collaboration t-cell antibody announces collaboration
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.